Escrito por estudiantes que aprobaron Inmediatamente disponible después del pago Leer en línea o como PDF ¿Documento equivocado? Cámbialo gratis 4,6 TrustPilot
logo-home
Document preview thumbnail
Vista previa 4 fuera de 38 páginas
Examen

UT Arlington NURS 5334 Advanced Pharmacology for NPs Exam 2 (pdf) | 2026/2027 | Advanced Pharm Q&A | Pharmacology

Document preview thumbnail
Vista previa 4 fuera de 38 páginas

This document helps you master NURS 5334 Advanced Pharmacology for Nurse Practitioners Exam 2 at UT Arlington via targeted Q&A with detailed rationales. It covers comprehensive neuropharmacology and autonomic nervous system agents—including cholinergic and adrenergic receptor subtypes (alpha, beta, nicotinic, muscarinic), mechanisms of synaptic transmission, and parasympathetic vs. sympathetic functions. You will master cardiovascular pharmacology with hypertension management (JNC-8 guidelines, ACE inhibitors, ARBs, CCBs, beta-blockers, thiazide diuretics), heart failure pharmacotherapy, and anticoagulation. The module also addresses pharmacogenomics and genetic variations in drug response. Engineered to maximize retention and sharpen clinical judgment, this targeted test pack simplifies complex pharmacology content, saving you valuable preparation time and ensuring you secure an A on your NURS 5334 Exam 2 assessment.

Vista previa del contenido

UT Arlington NURS 5334 Exam 2 (pdf) | 2026/2027 | Advanced
Pharmacology for NPs Q&A | Pharmacology

1. A patient with chronic kidney disease (Stage 4) is prescribed a medication
that is primarily renally excreted. Which of the following dose adjustments is
most appropriate?

A) A higher dose to achieve a therapeutic effect

B) A lower dose or longer dosing interval to prevent toxicity

C) The same dose as a patient with normal renal function

D) An increased frequency of administration

Correct Answer: A lower dose or longer dosing interval to prevent toxicity

Rationale: In renal impairment, drug clearance is reduced, leading to drug
accumulation and increased risk of toxicity. Dose reduction or extended
dosing intervals are required to maintain safe therapeutic levels.



2. A drug has a half-life of 24 hours. Approximately how many hours will it
take for the drug to reach steady state?

A) 24 hours

B) 48 hours

C) 120 hours

D) 240 hours

Correct Answer: 120 hours

Rationale: Steady state is achieved after approximately 4-5 half-lives. With a
half-life of 24 hours, 4-5 half-lives equal 96-120 hours.



3. A patient with heart failure is prescribed digoxin. Which physiological
change associated with aging would most likely increase the risk of digoxin
toxicity?

A) Increased glomerular filtration rate

B) Decreased lean body mass

C) Increased hepatic blood flow

,D) Decreased serum albumin

Correct Answer: Decreased serum albumin

Rationale: Aging is associated with decreased serum albumin. Digoxin is
moderately protein-bound. Lower albumin levels increase the free (active)
fraction of the drug, leading to a greater pharmacological effect and higher
risk of toxicity.



4. A weak acid drug with a pKa of 4.4 is administered orally. In which part of
the gastrointestinal tract will absorption be most rapid?

A) Mouth (pH 7.0)

B) Stomach (pH 1.5)

C) Duodenum (pH 6.0)

D) Colon (pH 7.5)

Correct Answer: Stomach (pH 1.5)

Rationale: Weak acids are non-ionized (lipid-soluble) in acidic environments,
facilitating absorption across cell membranes. The stomach's acidic pH
promotes the non-ionized form of a weak acid, enhancing absorption.



5. A patient is prescribed a drug that is a weak base. Which change in urine
pH would most significantly decrease the excretion of this drug?

A) Acidic urine pH

B) Alkaline urine pH

C) Neutral urine pH

D) Fluctuating urine pH

Correct Answer: Alkaline urine pH

Rationale: Weak bases are ionized (trapped) in acidic environments and are
more readily excreted in acidic urine. In alkaline urine, a weak base remains
non-ionized, which promotes passive reabsorption back into the bloodstream,
decreasing excretion.

,6. A patient is prescribed a drug that is highly protein-bound. Which of the
following conditions would most likely increase the risk of toxicity from this
drug?

A) Hypoalbuminemia

B) Hyperalbuminemia

C) Decreased hepatic blood flow

D) Increased glomerular filtration rate

Correct Answer: Hypoalbuminemia

Rationale: Hypoalbuminemia results in fewer protein-binding sites, leading to
an increased free (active) fraction of highly protein-bound drugs. This can
precipitate toxicity even at standard doses.



7. A drug has a volume of distribution (Vd) of 50 L. This indicates that the
drug:

A) Is confined to the vascular space

B) Is extensively distributed into tissues

C) Is highly protein-bound

D) Has poor lipid solubility

Correct Answer: Is extensively distributed into tissues

Rationale: A large volume of distribution suggests the drug is extensively
distributed into tissues, often due to high lipid solubility and binding to tissue
proteins, rather than being confined to the plasma.



8. Which of the following drugs is a non-depolarizing neuromuscular blocker?

A) Succinylcholine

B) Rocuronium

C) Neostigmine

D) Atropine

Correct Answer: Rocuronium

, Rationale: Rocuronium is a non-depolarizing neuromuscular blocker that
competitively blocks acetylcholine at the neuromuscular junction.
Succinylcholine is a depolarizing blocker. Neostigmine is a cholinesterase
inhibitor, and atropine is a muscarinic antagonist.



9. A patient is receiving succinylcholine for procedural sedation. Which
adverse effect is most concerning with this drug?

A) Tachycardia

B) Hyperkalemia

C) Hypotension

D) Bronchospasm

Correct Answer: Hyperkalemia

Rationale: Succinylcholine can cause a rapid release of potassium from
muscle cells, leading to life-threatening hyperkalemia, especially in patients
with burns, crush injuries, or neuromuscular disorders.



10. A patient is prescribed a drug that acts as a direct-acting cholinergic
agonist. Which of the following effects is expected?

A) Mydriasis

B) Tachycardia

C) Increased gastrointestinal motility

D) Bronchodilation

Correct Answer: Increased gastrointestinal motility

Rationale: Cholinergic agonists stimulate the parasympathetic nervous
system, leading to effects such as increased gastrointestinal motility, miosis,
bradycardia, and bronchoconstriction.



11. A patient with glaucoma is prescribed pilocarpine eye drops. What is the
mechanism of action of this drug?

A) Alpha-1 adrenergic receptor blockade

Información del documento

Subido en
13 de agosto de 2026
Número de páginas
38
Escrito en
2026/2027
Tipo
Examen
Contiene
Preguntas y respuestas
$15.99

¿Documento equivocado? Cámbialo gratis Dentro de los 14 días posteriores a la compra y antes de descargarlo, puedes elegir otro documento. Puedes gastar el importe de nuevo.
Escrito por estudiantes que aprobaron
Inmediatamente disponible después del pago
Leer en línea o como PDF

Seller avatar
ExamStudy
3.0
(1)
Vendido
8
Seguidores
0
Artículos
1067
Última venta
1 día hace




Por qué los estudiantes eligen Stuvia

Creado por compañeros estudiantes, verificado por reseñas

Calidad en la que puedes confiar: escrito por estudiantes que aprobaron y evaluado por otros que han usado estos resúmenes.

¿No estás satisfecho? Elige otro documento

¡No te preocupes! Puedes elegir directamente otro documento que se ajuste mejor a lo que buscas.

Paga como quieras, empieza a estudiar al instante

Sin suscripción, sin compromisos. Paga como estés acostumbrado con tarjeta de crédito y descarga tu documento PDF inmediatamente.

Student with book image

“Comprado, descargado y aprobado. Así de fácil puede ser.”

Alisha Student

Preguntas frecuentes